Suchergebnisse - "Cook, Gordon"

PubPharm (18)

1

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Kaiser, M. | Hall, A. | Walker, K. | +17

2

Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma

enthalten in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners | 2023

von Mateos, M. | Rigaudeau, S. | Basu, S. | +14

3

Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma : A real-world multicentre UK retrospective analysis

enthalten in: British journal of haematology | 2023

von McMillan, A. | Basu, S. | Karunanithi, K. | +22

4

Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial

enthalten in: British journal of haematology | 2022

von Chan, W. | Counsell, N. | de Tute, R. | +24

5

Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US

enthalten in: Annals of hematology | 2021

von Davies, F. | Rifkin, R. | Costello, C. | +24

6

Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial

enthalten in: Haematologica | 2021

von Jackson, G. | Davies, F. | Pawlyn, C. | +21

7

Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma : results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial

enthalten in: British journal of haematology | 2021

von Jackson, G. | Pawlyn, C. | Cairns, D. | +21

8

Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age : subgroup analysis of the phase 3 CASTOR and POLLUX studies

enthalten in: Haematologica | 2020

von Mateos, M. | Spencer, A. | Nooka, A. | +16

9

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Jackson, G. | Davies, F. | Pawlyn, C. | +20

10

Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial)

enthalten in: British journal of haematology | 2019

von Popat, R. | Brown, S. | Flanagan, L. | +10